Faster global financial news!
Revolution Medicines
-
BeiGene's net profit for the first half of the year surged by 385.8% year-on-year to US$464 million, with total revenue reaching US$3.219 billion.
BeiGene announced its results for the six months ended June 30, 2026, with total revenue increasing by 32.3% year-on-year. The global sales of its flagship product, BRUKINSA® (zanubrutinib), reached U
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
-
BeiGene's net profit for the first half of the year surged by 385.8% year-on-year to US$464 million, with total revenue reaching US$3.219 billion.
BeiGene announced its results for the six months ended June 30, 2026, with total revenue increasing by 32.3% year-on-year. The global sales of its flagship product, BRUKINSA® (zanubrutinib), reached U
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
- No data
Revolution Medicines
24H Trending
-
1
Bitcoin Price Breaks $77,000: Multiple Factors Drive Current Rally
-
2
US banks are owed $349B by private credit funds, as PIK interest payments rise to 10% of loans
-
3
Al Jazeera: Israeli attacks on Gaza kill at least 4 Palestinians, UN Human Rights Office warns of ethnic cleansing risk
-
4
Musk retweeted that as of October 31, the number of Starlink satellites has reached 11,184, accounting for 66% of the total active satellites globally.
-
5
Bitcoin staking protocol b14g says $97 million CORE drained, pauses contracts
-
6
Nikkei Asia: Overseas entities' JPY bond issuance reaches a record $16 billion as the AI funding race spreads to Japan
-
7
Al Jazeera: Palestinian Man Succumbs to Injuries After Israeli Drone Strike in Gaza
-
8
SpaceXAI, the AI division of SpaceX, failed to dismiss an air pollution lawsuit filed by the NAACP, with the judge ruling that the case will proceed.
-
9
Chainalysis: Ethereum Reorg Causes THORChain Emergency Pause, Accidentally Delays Binance Hacked Funds Laundering
-
10
Binance confirmed that it has transferred 7,499 Bitcoins to the SAFU fund, stating that it has recovered 90% of the stolen assets and pledged to rebuild the emergency fund to approximately $1 billion.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
